SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Feb 3, 2012
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: Feb. 3, 2012 · CIK: 0001213037 · Accession: 0001104659-12-006637
AI Filing Summary & Sentiment
File numbers found in text: 000-54556
Referenced dates: January 27, 2012
Letter
VIA EDGAR TrovaGene, Inc. (the “Company”) Amendment No. 1 to Registration Statement on Form 10-12G/A Filed December 30, 2011 File No. 000-54556
Dear Mr. Greenspan:
The Company is in receipt of your comment letter dated January 27, 2012. The Company would like to respectfully request an extension to respond to the comment letter to February 13, 2012.
Respectfully yours,
/s/ Jeffrey J. Fessler
Show Raw Text
CORRESP 1 filename1.htm Sichenzia Ross Friedman Ference LLP 61 Broadway New York, NY 10006 February 3, 2012 VIA EDGAR U. S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-4720 Attn: Dan Greenspan Re: TrovaGene, Inc. (the “Company”) Amendment No. 1 to Registration Statement on Form 10-12G/A Filed December 30, 2011 File No. 000-54556 Dear Mr. Greenspan: The Company is in receipt of your comment letter dated January 27, 2012. The Company would like to respectfully request an extension to respond to the comment letter to February 13, 2012. Respectfully yours, /s/ Jeffrey J. Fessler